# Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

> **NCT05809336** · PHASE2,PHASE3 · COMPLETED · sponsor: **Beijing Friendship Hospital** · enrollment: 172 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Inosine 0.2g orally 3 times/day
- **DRUG:** PD-1/PD-L1 inhibitor ,chemotherapy/targeting

## Key facts

- **NCT ID:** NCT05809336
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05809336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05809336, "Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05809336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*